Key Highlights

● US-listed AstraZeneca shares were up 4.87% before the bell as of about 7:30 a.m. ET.

● The nine-month and third-quarter 2026 results were published at 7:00 a.m. GMT on Friday.

● Enhertu won European approval on October 27 for HER2-positive early breast cancer with residual disease.

● An investor and analyst webcast at 10:30 a.m. ET is the next scheduled event.

AstraZeneca (NYSE:AZN) shares were moving higher in early US trading on Friday after the Anglo-Swedish drugmaker published its nine-month and third-quarter 2026 results. Market data showed the US-listed shares up 4.87% before the bell, as of about 7:30 a.m. ET, and a live market blog described the release as an Earnings beat.

The company said ahead of time that the announcement would be posted at 7:00 a.m. GMT on Friday, which is 3:00 a.m. ET. The release itself had not been reviewed at the time of writing, so revenue, core Earnings Per Share and guidance figures are not cited. The full numbers are on the company's Investor relations page.

What is clear is the direction of the reaction. A gain of nearly 5% would be a large move for a company of AstraZeneca's size, and it stands out on a morning when Nasdaq-100 futures were down about 2.6% around 8 a.m. ET, according to market data. The FTSE 100 in London, where AstraZeneca is one of the heaviest weights, was modestly higher in early trading.

A busy October for the pipeline

The report follows a run of clinical and regulatory news. On Oct. 27, AstraZeneca and partner Daiichi Sankyo won European approval for Enhertu as an adjuvant treatment for HER2-positive early breast cancer in patients with residual disease, based on DESTINY-Breast05 data showing a 53% lower risk of invasive recurrence or death versus T-DM1, according to a company release.

At the ESMO congress, the company presented overall survival data from several Phase III trials. Imfinzi combined with Amgen (NASDAQ:AMGN)'s tarlatamab cut the risk of death by 58% as first-line maintenance in extensive-stage small cell lung cancer in the DeLLphi-305 trial. Tagrisso plus savolitinib reduced the risk of progression or death by 45% in the SAFFRON study, and a US application has been submitted.

Earlier in the month, Tezspire, developed with Amgen, met both co-primary endpoints in a Phase III trial in eosinophilic esophagitis, and Zegfrovy became available in the US for a form of lung cancer after an accelerated FDA approval. Not every readout was clean: the sonesitatug vedotin gastric cancer trial improved survival, but an independently reviewed progression-free survival measure missed statistical significance.

Why it matters today, and what comes next

AstraZeneca's US shares trade on the New York Stock Exchange, which places the stock in the NYSE Composite. For US investors, it sits alongside Eli Lilly (NYSE:LLY) and other large drugmakers that have benefited from a rotation into health care. The Health Care Select Sector SPDR fund rose 2.4% to a record on Thursday, according to market data, while technology and communication services fell.

That rotation has a clear driver this week. Results from Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) raised fresh questions about the cash being spent on artificial intelligence, and Alphabet (NASDAQ:GOOGL) suffered its worst day on record on Thursday. Pharmaceutical companies with visible earnings growth offer a contrast, although Treasury yields near 5%, with the 10-year at about 4.94% to 4.99% this morning, still weigh on long-duration Growth Stocks of all kinds.

Risks include drug pricing pressure in the US, Patent expiries and the usual uncertainty in late-stage trials. The next scheduled event is the company's investor and analyst webcast at 2:30 p.m. GMT, or 10:30 a.m. ET, where management is expected to take questions on the quarter and the outlook. Traders will watch whether the early gain holds once the session opens and the wider market's tech selloff plays out.